Parallax Volatility Advisers
AUPH icon

Parallax Volatility Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Parallax Volatility Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,000
Closed -$166K – 2011
2024
Q2 		$166K Buy
29,000
+26,000
+867% +$137K ﹤0.01% 1631
2024
Q1 		$15K Buy
+3,000
New +$20.4K ﹤0.01% 1681
2023
Q3 		– Sell
-600
Closed -$5.81K – 2275
2023
Q2 		$5.81K Buy
+600
New +$6.23K ﹤0.01% 2216
2022
Q1 		– Sell
-30,100
Closed -$688K – 2855
2021
Q4 		$688K Sell
30,100
-34,100
-53% -$808K ﹤0.01% 2054
2021
Q3 		$1.42M Buy
+64,200
New +$1.02M ﹤0.01% 1812
2017
Q4 		– Sell
-50,000
Closed -$314K – 3944
2017
Q3 		$314K Hold
50,000
– – ﹤0.01% 1360
2017
Q2 		$307K Sell
50,000
-84,400
-63% -$569K ﹤0.01% 1348
2017
Q1 		$987K Sell
134,400
-20,400
-13% -$94.2K ﹤0.01% 1163
2016
Q4 		$325K Buy
+154,800
New +$498K ﹤0.01% 1680

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallax Volatility Advisers's AUPH Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 49,279 shares — an estimated $396K sold.

Parallax Volatility Advisers first reported a position in AUPH in Q4 2016 and held it in 19 quarters. The position peaked at $2.56M in Q4 2021. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 49,279 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $396K.
  • Parallax Volatility Advisers first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 19 quarters.
  • Parallax Volatility Advisers's Aurinia Pharmaceuticals position peaked at $2.56M in Q4 2021.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.